Clinical Trial Update: Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy

View source ↗

Summary

A pharmacokinetic study of peramivir in hospitalized adults undergoing continuous renal replacement therapy was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Rapivab (peramivir) (peramivir)

Snippet

Sponsor: Midwestern University | Conditions: Influenza, Renal Failure | Status: WITHDRAWN